Loading...
•
Mar 31, 2020
Capricor Q1 2020 Earnings Report
Capricor reported financial results for Q1 2020 and provided a corporate update.
Key Takeaways
Capricor Therapeutics reported a net loss of $2.1 million for the first quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $13.2 million as of March 31, 2020. They also made advances in their DMD and COVID-19 pipeline development.
Final top-line 12-month results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of Upper Limb (PUL) 2.0 (p=0.05).
Reported 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002 Under Compassionate Use Pathway.
Expanded Access Protocol Approved by FDA to Treat Critical COVID-19 Patients.
Appointed Stephen J. Gould, Ph.D. to lead Capricor’s Exosome-Based Platform Vaccine Approach Against COVID-19.
Forward Guidance
Capricor expects 2020 to be a transformative year with clarity on next steps in its DMD program, the results from our expanded access program in COVID-19 and the planned expansion of Capricor’s exosome platform technology for vaccine development.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...